Clinical trials: Atopic Dermatitis
PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis
Natural History of Severe Allergic Inflammation and Reactions
Background: Allergic inflammation is central to allergy-related diseases and disorders, such as asthma, food allergies, and atopic dermatitis.
- Conditions
- PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis, OSMR Deficiency, Primary Localized Cutaneous Amyloidosis
- Trial name
- NCT01164241
- Where
- United States
- Volunteers
- 945 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on…
- Trial name
- ADVISE MCOS (NCT05081557)
- Where
- 140 sites in Argentina, Australia and 14 more
- Volunteers
- 873 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis.
- Trial name
- NCT06280716
- Testing
- Lebrikizumab, Topical Corticosteroid
- Where
- 46 sites in China, South Korea
- Volunteers
- 301 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Switch-Up (NCT06389136)
- Testing
- Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
- Where
- 129 sites in United States, Canada and 7 more
- Volunteers
- 184 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Start Up (NCT06461897)
- Testing
- Upadacitinib, Dupilumab
- Where
- 150 sites in United States, Argentina and 24 more
- Volunteers
- 699 people
- Sponsor
- AbbVie
Atopic Dermatitis, Eczema
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities.
- Trial name
- NCT06756438
- Testing
- Study product
- Where
- Poland
- Volunteers
- 88 people
- Sponsor
- NAOS Les Laboratoires
Atopic Dermatitis, Alopecia Areata
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)).
- Trial name
- NCT07242638
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Atopic Dermatitis
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female.
- Trial name
- NCT07762833
- Testing
- Nemolizumab 30 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Asthma, Asthma in Children
Allergy, Asthma, and Atopic Eczema in Finland
The summary is available at --> https://www.finnatopy.fi/summary
- Conditions
- Asthma, Asthma in Children, Allergy, Rhinitis, Allergic
- Trial name
- FinnATOPY (NCT06330974)
- Testing
- No intervention, No Intervention: Observational Cohort
- Where
- Finland
- Volunteers
- 1,200,000 people
- Sponsor
- Tampere University
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
Background: Allergic or sinus diseases can affect the skin, sinuses, airways, and other parts of the body. Examples include pollen and environmental allergies, food allergies, asthma, and eczema.
- Trial name
- NCT06732414
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy.
- Trial name
- ADsolve (NCT07006792)
- Testing
- Lebrikizumab
- Where
- 66 sites in United States, Argentina and 3 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD)
A Phase III Study of GS101 Injection to Dupixent®
This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07386743
- Testing
- GS101 injection, DUPIXENT®
- Where
- China
- Volunteers
- 572 people
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Atopic Dermatitis (AD)
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S.
- Trial name
- NCT07411755
- Testing
- GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent®
- Where
- China
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio.
- Trial name
- NCT07754786
- Testing
- Dupilumab Injection, IBI3027
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Eczema, Atopic Dermatitis
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease.
- Trial name
- NCT00605878
- Where
- United States
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Food Allergy, Loeys-Dietz Syndrome
Natural History and Genetics of Food Allergy and Related Conditions
Background: About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them.
- Conditions
- Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
- Trial name
- NCT02504853
- Where
- United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Dermatitis, Atopic
A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis (AtD).
- Trial name
- NCT05486208
- Testing
- LY3844583
- Where
- 3 sites in United States, Japan
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company